Ad
related to: worldwide clinical trials address
Search results
FSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in...
Digital Journal· 1 day ago(NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments ...
Cystic fibrosis: global clinical trials landscape and treatments
Clinical Trials Arena via Yahoo Finance· 5 days agoAffecting more than 162,000 patients worldwide, cystic fibrosis affects respiratory health and...
The Michael J. Fox Foundation Applauds Passage of National Plan to End Parkinson's Act in Congress
Clearfield Progress· 6 days agoThe National Plan establishes a federal advisory council dedicated to finding a cure for Parkinson's disease. NEW YORK, May 23, 2024 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's ...
Terran Biosciences prepares for trials of schizophrenia drug
Clinical Trials Arena via Yahoo Finance· 5 days agoTreatment for schizophrenia primarily involves the use of antipsychotic drugs, which...positive...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further...
CBS 47 Fresno· 4 days agoIn the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) ...
Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024
KTLA-TV Los Angeles· 5 days agoShanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced ...
3 Biotech Stocks That Could Be Millionaire-Makers: May Edition
InvestorPlace· 4 days agoAs we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing ...
WFRV 5 Green Bay· 4 days agoNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session ...
Merck to Acquire EyeBio
Morningstar· 7 hours agoMerck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eyebiotech Limited (EyeBio), a privately held ophthalmology-focused biotechnology company, today announced that the ...
New malaria vaccine delivered for the first time
NPR· 5 days agoThis is what made WHO’s approval of the second malaria vaccine such welcome news. Tinto ran the clinical trials in Burkina Faso that led to its recommendation. Across four ...
